Medivir AB (publ) (MVRBF) Stock Price, News & Analysis

Company Overview

Medivir AB (publ) is a Sweden-based biotechnology company focused on the discovery, development and commercialization of innovative pharmaceuticals in the fields of oncology and viral diseases. The company’s expertise lies in small-molecule chemistry and targeted drug design, with particular emphasis on liver-directed therapies and protease inhibitors. Medivir operates a research facility in Huddinge, Sweden, where it advances its proprietary platform technologies to identify new candidate molecules.

Historically, Medivir gained prominence through the discovery of simeprevir, a hepatitis C virus protease inhibitor that was licensed to Janssen Pharmaceuticals and marketed under the brand name Olysio. Building on this success, the company has transitioned its pipeline toward oncology by developing a liver-targeted polymerase inhibitor, MIV-818, which entered early clinical studies for primary and secondary liver cancers. Additional preclinical programs are exploring novel mechanisms of action against solid tumors.

Medivir collaborates with global pharmaceutical partners to leverage its medicinal chemistry know-how and accelerate clinical development. Its strategic alliances extend across Europe and North America, enabling access to global trial networks and regulatory expertise. The company is publicly listed on Nasdaq Stockholm and maintains a dedicated corporate governance framework in line with Swedish and European regulations.

Underpinning its operations is a commitment to rigorous research and translational science. Medivir’s multidisciplinary team of chemists, biologists and clinicians works to advance its oncology portfolio through proof-of-concept studies, with the goal of delivering differentiated therapies for patients with unmet medical needs. The company continues to explore new targets and expand its pipeline via in-house discovery and external collaborations.

Key Stats

• Today's Range: $0.82 to $0.82
• 50-Day Range: $0.82 to $0.82
• 52-Week Range: $0.68 to $0.82
• Volume: N/A
• Average Volume: 925 shs
• Market Capitalization: N/A
• P/E Ratio: 0.03
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MVRBF Stock Analysis - Frequently Asked Questions

How have MVRBF shares performed this year?

Medivir AB (publ)'s stock was trading at $0.82 at the beginning of the year. Since then, MVRBF shares have increased by 0.0% and is now trading at $0.82.

How do I buy shares of Medivir AB (publ)?

Shares of MVRBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MVRBF
• CIK: N/A
• Web: www.medivir.com
• Phone: (685) 468-3100
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.03
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A